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CONSENSUS ARTICLE
Genetic risk factors for clozapine-induced neutropenia and
agranulocytosis in a Dutch psychiatric population
K van der Weide1, H Loovers1,2, K Pondman1, J Bogers3, T van der Straaten4, E Langemeijer5, D Cohen6, J Commandeur7 and
J van der Weide1,2
Prescription of clozapine is complicated by the occurrence of clozapine-induced reduction of neutrophils. The aim of this study was
to identify genetic risk factors in a population of 310 Dutch patients treated with clozapine, including 38 patients developing
neutropenia and 31 patients developing agranulocytosis. NQO2 1541AA (NRH quinone oxidoreductase 2; protects cells against
oxidative metabolites) was present at a higher frequency in agranulocytosis patients compared with control (23% versus 7%,
P= 0.03), as was ABCB1 (ABC-transporter-B1; drug efflux transporter) 3435TT (32% versus 20%, P = 0.05). In patients developing
neutropenia, ABCB1 3435TT and homozygosity for GSTT1null (glutathione-S-transferase; conjugates reactive clozapine metabolites
into glutathione) were more frequent compared with control (34% versus 20%, P = 0.05 and 31% versus 14%, P = 0.03), whereas
GSTM1null was less frequent in these patients (31% versus 52%, P = 0.03). To investigate whether combinations of the identified
genetic risk factors have a higher predictive value, should be confirmed in a larger case–control study.
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INTRODUCTION
Clozapine is an atypical antipsychotic drug and is used with high
efficacy in the treatment of refractory schizophrenia, defined as an
insufficient treatment result after two consecutive antipsychotic
trials.1,2 However, the use of clozapine is limited due to the risk of
developing agranulocytosis, a potentially lethal drop in number of
neutrophils, which occurs in about 0.4–0.8% of patients.3 Because
clozapine-induced agranulocytosis (CIA) has a fatality rate of
2.2–4.2%, even while patients are monitored,3 its prescription is
subject to strict regulations and requires regular control of white
blood cells. The risk for CIA is highest within the first 18 weeks,
although cases have been described in which CIA occurred years
later.4,5 Physicians prescribing clozapine are confronted with
several dilemmas. Should patients who oppose blood drawing
be started on clozapine? Should patients with a decrease in
neutrophils be continued on clozapine? How to proceed when a
patient is prescribed clozapine and is having a fever? A better
assessment of the individual risk could aid in decision making in
clozapine treatment regimen and blood monitoring protocols. As
twin studies have indicated a genetic component, the individual
risk might be predicted by genetic polymorphisms.6,7 Several
association studies have been performed in order to identify the
genetic factors determining the susceptibility for CIA and
neutropenia. Roge et al.8 suggested that the mechanism behind
CIA and clozapine-induced neutropenia may be different.
The first associations between genetic markers and CIA were
found for alleles of human leukocyte antigens (HLAs), implicating
a role for the immune system in the pathogenesis of agranu-
locytosis.9 However, the initial studies on the association of CIA
with HLA genes often concerned small numbers (~100 patients in
total), extended HLA haplotypes and depended on ethnicity
(reviewed in Chowdhury et al.10). The generally complex associa-
tions with HLA genes were suggested to originate from linkage
disequilibrium with other polymorphisms located in nearby
genes.11 Two candidate genes, located close to genes of the
major histocompatibility complex are TNF-α (tumor necrosis factor
alpha) and Hsp70-2 (heat shock protein 70-2). Clozapine treatment
is accompanied by an increase in TNF-α.12,13 Moreover, TNF alleles
are in linkage disequilibrium with HLA haplotypes and one study
showed an association between TNF microsatellites and CIA.14,15
Corzo et al.11,16 observed a linkage disequilibrium between the
Hsp70-2 8.5 kb/9 kb PstI polymorphic site and CIA-associated HLA
haplotypes. Consequently, an association between this poly-
morphic site and CIA was observed.11
CIA is generally considered to be mediated by the oxidative
metabolism of clozapine in neutrophils by the combination of
NAD(P)H-oxidase and myeloperoxidase (MPO).17,18, The reactive
nitrenium ions and/or radicals formed have been shown to cause
increased levels of oxidative stress and induction of apoptotic
pathways in neutrophils of patients with CIA.19 Both MPO and the
NAD(P)H-oxidase subunit CYBA (cytochrome b-245 light chain) are
genetically determined. The CYBA 640A4G mutation is associated
with lower NAD(P)H-oxidase activity, and the -463G4A mutation
in the promotor site of MPO leads to lower MPO expression. A
lower frequency would be expected in CIA patients, because these
mutations will result in lower clozapine bioactivation. However,
previous studies did not show statistically significant differences,
possibly due to a small sample size (Table 5).20,21
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Next to genetic polymorphisms at the level of clozapine-
bioactivating enzymes, also polymorphisms of protective enzymes
involved in inactivation of reactive clozapine metabolites poten-
tially determine susceptibility to CIA. Quinone oxidoreductases
NQO1 and NQO2, which protect cells against oxidative metabo-
lites, such as quinones and quinoneimines, are known to be
strongly genetically determined.22,23 Their role in inactivation of
reactive clozapine metabolites has not yet been demonstrated
experimentally. A small association study on the role of NQO2
polymorphisms in CIA showed a higher frequency of the NQO2
1541A allele for CIA patients compared with control patients
(Table 5).24 The nucleotide substitution 1541G4A in the first
intron is believed to affect a binding site for the myeloid zinc
finger protein MZF1,24 which has a general role in the regulation
of hematopoietic gene expression.25 This suggests that the
resulting lower expression of NQO2 might increase the risk for
CIA. The role of polymorphism NQO1 C609T in CIA, which results in
very low expression levels of NQO1,26 has not yet been studied.
Several glutathione S-transferases (GSTs) have been shown to
catalyze the conjugation of reactive clozapine metabolites into
glutathione.27 In humans, marked interindividual differences exist
in the expression of class Alpha (GSTA), Mu (GSTM), Pi (GSTP) and
Theta (GSTT) GSTs,28 due to genetic polymorphisms. In case of
GSTM1 and GSTT1, part of the population completely lack the
enzyme as a consequence of genetic deletions (‘null genotypes’).
Several studies have shown association of these GST-null
genotypes with increased sensitivity to antitumor compounds29
and an increased susceptibility to adverse drug reactions.30 The
presence of GSTA1 C-69T, one of the four linked base substitutions
present in the GSTA1*B variant, results in a low hepatic expression
in homozygous patients.31 Dependent of the substrate, the GSTP1
A313G mutation can result in altered catalytic efficiency, due to
changes in the active site29 and was shown to be associated with a
better response to platinum-based chemotherapy.32,33 Generally
speaking, reduction in the ability to detoxify electrophilic reactive
metabolites by GSTs may result in a higher risk for toxicity due to a
higher exposure to the reactive metabolites.
Clozapine serum levels are influenced by polymorphisms in the
P-glycoprotein (P-gp) transporter gene ABCB1 (MDR1).34,35 How-
ever, no direct relationship has been observed between clozapine
serum levels and leukocyte counts.36 Interestingly, one case report
described a CIA patient with a normal clozapine serum level, but
an abnormally high clozapine level in neutrophils.37 Furthermore,
one case report describes twin brothers who developed CIA and
were heterozygous for both ABCB1 C3435T and G2677T/A.6 These
data suggest a link between ABCB1 polymorphisms and the risk
for CIA, possibly by affecting clozapine levels in neutrophils,
although further research is warranted.
The aim of this study was to investigate the above mentioned
genetic risk factors for clozapine-induced neutropenia and
agranulocytosis in a large Dutch psychiatric population prescribed
with clozapine. Thirteen candidate gene polymorphisms were
selected for investigation. The choice of polymorphism was
based on reported association with CIA in other populations
(CYBA A640G, HLA-DQB1 G6672C, Hsp70-2 G1276A, MPO G-463A
(rs2333227) and NQO2 G1541A), putative role in CIA based on
similarity with reported CIA-associated polymorphisms (NQO1
C609T (rs1800566) and TNF G-308A(rs1800629)) and putative role in
clozapine transport (ABCB1 G2677T/A (rs2032582) and ABCB1
C3435T (rs1045642)) and elimination (GSTA1 C-69T, GSTP1 A313G,
and GSTT1 and GSTM1 gene deletion).
MATERIALS AND METHODS
Patients and setting
This retrospective study was conducted in the Dutch Psychiatric
Hospital GGz Centraal location Meerkanten and in the Mental
Health Services Rivierduinen. According to national guidelines.
Measurement of the number of leukocytes was performed just
before the start of clozapine treatment, once a week in the first
18 weeks and once a month until the end of treatment.38 Patient
selection occurred based on the criteria for CIA and neutropenia
as described by the Food and Drug Administration.38,39 CIA
patients were selected based on at least one neutrophil count
⩽ 500 μl− 1. Neutropenia patients were selected on at least one
neutrophil count between 500 μl and 1500 μl− 1 or two neutrophil
counts o2000 μl− 1 during clozapine treatment. Patients were
excluded when a neutrophil count o2000 μl− 1 was recorded
before the start of clozapine treatment.
Control patients were selected for prescription of clozapine for
at least 1 year, no record of either neutrophil counts o2000 μl− 1
or leukocyte counts o4000 μl− 1. In all groups patients aged
under 18 were excluded, as were patients for whom DNA samples
could not be obtained. For patients of GGz Centraal, genotyping of
CYP2D6 and CYP2C19 polymorphisms was performed routinely
upon admission to the clinic and anonymized DNA samples were
stored at − 70 °C for research purposes and therefore for this
study. For patients of Mental Health Services Rivierduinen, DNA
samples are not routinely collected, therefore DNA was obtained
after selection of the patients.
The condition of at least 1 year of clozapine use was justified by
the fact that 80% of the total incidence of CIA occurs in the first
18 weeks of use,38,40 which is why in Europe patients are weekly
monitored for blood cell counts during these first months. Less
frequent cases of agranulocytosis were reported to occur during
the first year,41,42 after which only incidental cases of CIA have
been reported after up to 19 years of clozapine use.5
The Medical Research Ethics Committee in Amsterdam assessed
the project and stated that it was not subject to further investiga-
tion under the Medical Research (Human Subjects) Act. The study
has been approved by the research board (Innova) of Psychiatric
Hospital GGz Centraal. Patients were not subjected to any
procedures besides routine clinical practice and were informed
on the use of data for research purposes. Data were excluded from
research upon objection.
Genotyping methods
Thirteen polymorphisms were selected for analysis: ABCB1 G2677T/
A (rs2032582), ABCB1 C3435T (rs1045642), CYBA A640G, HLA-DQB1
G6672C, Hsp70-2 G1276A, MPO G-463A (rs2333227), NQO1 C609T
(also known as NQO1*2, rs1800566), NQO2 G1541A, TNF G-308A
(rs1800629), GSTA1 C-69T, GSTP1 A313G, and GSTT1 and GSTM1
gene deletion. The Hsp70-2 G1276A corresponds to the
polymorphic PstI site (8.5 and 9.0 kb allele) investigated in
previous studies.43 Primer sequences, PCR extension and elonga-
tion conditions, restriction enzymes and length of obtained DNA
fragments are shown in Table 1.
With exception of HLA-DQB1 and the GSTs, determinations were
performed using allele-specific digestion of PCR products. Primer
sequences and PCR extension and elongation conditions are
shown in Table 1. HLA-DQB1 determination was performed using
allele-specific reverse primers in combination with a common
forward primer. For all polymorphisms except the GSTs, PCR
reaction mixes contained 2–4 ng μl− 1 DNA, 0.4 μM of each primer,
0.2 mM dNTPs, 0.04–0.1 U μl− 1 Thermoprime Plus DNA polymer-
ase (Abgene House, Epsom, UK) and 1.0x ReddyMix PCR buffer. For
NQO2 G1541A, a semi-nested PCR was performed using primers
HL1541F+HL1541R on the PCR product obtained with primers
HL1541F+HL1541R1. PCR products were digested and analyzed by
gel electrophoresis. For MPO G-463A and ABCB1 G2677T/A, gel
electrophoresis was performed after addition of SDS (1% final
concentration) to the digestion products.
The presence of at least one GSTM1 and/or GSTT1 allele was
determined as described by Arand et al.44 Briefly, 10 ng of DNA
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was taken to amplify representative sequences of the genes of
GSTT1, GSTM1 and albumin (as reference gene). Hotstart PCR
mastermix was used from Qiagen (Venlo, The Netherlands). The
PCR products of the GSTT1 and GSTM1 were detected by agarose
gel electrophoresis. The rs1695 genotype of GSTP1-1 (mutation
A313G; Ile105Val) was determined by allele-specific PCR using a
predesigned Taqman assay (C___3237198_20) from Life Technol-
ogies (Nieuwerkerk a/d IJssel, The Netherlands) and analyzed on
the 7500 real time PCR system (Life Technologies). The presence of
GSTA1 C-69T was determined by pyrosequencing on a Pyrose-
quencer 96MA (Qiagen). Sequence to analyze was C/TCTTCTTTCA
and dispensation order was GTCGTCTCA.
Table 1. PCR primers and conditions and digestion patterns






Forward TGCAATAGCAGGAGTTGTa 5ʹ95 °C, (30ʺ95 °C, 30ʺ58 °C,
30ʺ72 °C) × 41, 5ʹ72 °C




Forward TGTTTTCAGCTGCTTGATGGb 5ʹ95 °C, (30ʺ95 °C, 30ʺ60 °C,
30ʺ72 °C) × 41, 5ʹ72 °C
BfuCI T: 197
Reverse AAGGCATGTATGTTGGCCTCb C:160+37
CYBA A640G Forward AGCAGTGGACGCCCATCGAGCCCAAc 5ʹ95 °C, (30ʺ95 °C, 30ʺ67 °C,
30ʺ72 °C) × 41, 5ʹ72 °C




Forward TTGGAGGCTTCGTGCTGG 5ʹ95 °C, (30ʺ95 °C, 30ʺ60 °C,








Hsp70 G1276A Forward TCCGAAGGACTGAGCTCTTGd 5ʹ95 °C, (30ʺ95 °C, 1ʹ60 °C, 5ʹ72 °
C) × 41, 10ʹ72 °C
PstI A: 2076
Reverse CAGCAAAGTCCTTGAGTCCCd G: 1137+939
MPO G-463A
Rs 2333227
Forward CGGTATAGGCACACAATGGTGAGe 5ʹ95 °C, (30ʺ95 °C, 30ʺ56 °C,
30ʺ72 °C) × 41, 3ʹ72 °C
AciI A: 355+61
Reverse GCAATGGTTCAAGCGATTCTTCe G: 171+123+61
NQO1 C609T
Rs 1800566
Forward AAGCCCAGACCAACTTCTf 5ʹ95 °C, (30ʺ95 °C, 30ʺ56 °C,
30ʺ72 °C) × 41, 3ʹ72 °C
HinfI C: 172T: 131+41
Reverse ATTTGAATTCGGGCGTCTGCTGf
NQO2 G1541A Forward CGGGCTGCTTAGGTTGGCACg 5ʹ95 °C, (30ʺ95 °C, 30ʺ59 °C,
30ʺ72 °C) × 41, 5ʹ72 °C





Forward AGGCAATAGGTTTTGAGGGCCATh 5ʹ95 °C, (30ʺ95 °C, 1ʹ60 °C, 1ʹ72 °
C) × 41, 5ʹ72 °C
NcoI G: 85+22A: 107
Reverse TCCTCCCTGCTCCGATTCCGh
GSTA1 C-69T Forward AGTAGGTGGCCCCTTGGC
reverse TGTCACCGTCCTGGCTCGAC (biotin)
Sequence primer GGCTTTTCCCTAACTTGAC
GSTT1 del Forward TTCCTTACTGGTCCTCACATCTC 15ʹ95 °C, (30ʺ95 °C, 30ʺ55ʹ °C,
30ʺ72 °C) × 35, 10ʹ72 °C
480 bp
Reverse TCACCGGATCATGGCCAGCA
GSTM1 del Forward GAACTCCCTGAAAAGCTAAAGC 15ʹ95 °C, (30”95 °C, 30ʺ55ʹ °C,
30ʺ72 °C) × 35, 10ʹ72 °C
215 bp
Reverse GTTGGGCTCAAATATACGGTGG
Albumin Forward GCCCTCTGCTAACAAGTCCTAC 15ʹ95 °C, (30ʺ95 °C, 30ʺ55ʹ °C,
30ʺ72 °C) × 35, 10ʹ72 °C
350 bp
Reverse GCCCTAAAAAGAAAATCGCCAATC
Allelic discrimination assays were adaptations from assays described by: aHüebner et al.45 bCascorbi et al.64 cInoue et al.65 dMilner et al.66 eLondon et al.67
fZhang et al.68 gOstrousky et al.24 hWilson et al.69
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For ABCB1 G2677T/A, no distinction could be made between
2677T and 2677A; for simplicity the allele was classified as the
more common 2677T in this manuscript.45 Assays were validated
by sequencing of one homozygous wild type, one homozygous
mutant and one heterozygous sample (BaseClear, Leiden, The
Netherlands). For HLA-DQB1, no homozygous 6672CC sample was
available for sequencing.
Statistics
We calculated the necessary sample size (25 cases) based on
a desired increased allele frequency in cases by 2.5-fold in case of
a frequency of 0.2 and a 1.6-fold increase of a frequency of 0.5,
assuming a 1:10 sample ratio of cases versus controls and
a significance level of α= 0.05 and 80% power (β= 0.2). Statistical
analyses were performed using SPSS for Windows (SPSS version
15.0, Chicago, IL, USA). Cases were grouped according to neu-
trophil counts (see above). Subgroups were based on genotype;
for all investigated polymorphisms differences in frequency of the
three possible genotypes (homozygous for one or the other allele
or heterozygous for both alleles) were analyzed, comparing
frequencies in neutropenia and CIA patients with control patients
and with each other. Statistical analyses for frequencies of
genotypes were performed using Fisher exact probability test,
showing two-tailed probability values. The strength of the
associations between the polymorphism with neutropenia and
CIA were expressed as odds ratios (ORs) with a 95% confidence
interval (CI).
RESULTS
A total of 310 patients treated with clozapine were included in
this study; 31 patients exhibited CIA, 38 patients had neutropenia
and 241 patients served as controls. Additional patient and
clozapine use information and co-medication are presented in
Tables 2a and 2b.
When comparing CIA patients with controls, as presented in
Table 3, of the polymorphisms previously reported to be
associated with CIA (CYBA 640, HLA-DQB1 G6672C, Hsp70-2
G1267A, NQO2 1541G and MPO G-463A) only NQO2 1541G had
significantly different allele and genotype frequencies. Absolute
numbers of different genotypes in the three different groups (CIA,
neutropenia and controls) are presented in Supplementary 1.
The NQO2 1541AA genotype, which is expected to result in low
NQO2 expression, was present at a higher frequency in the case
population (23%) than in the control population (7%; P = 0.004;
Table 3) and the NQO2 1541GG wild-type genotype was present in
53% of the control patients compared with only 29% in CIA
patients. The odds ratio for developing CIA was 5.5 times higher
for the homozygous mutant 1541AA genotype (Table 4).
A genetic test based on detection of NQO2 1541AA would have
a sensitivity of 23% and a specificity of 97%, with a negative
predictive value of 90%. For the other polymorphisms which were
not yet studied in relation to CIA (ABCB1 G2677T, ABCB1 C3435T,
NQO1 C609T, TNFα G-308A, GSTA1 -69T, GSTP1 313G, GSTT1null, and
GSTM1null), the ABCB1 3435TT genotype was more frequent in CIA
patients (32 versus 20% in controls; P = 0.05; Table 3) and the wild-
type ABCB1 3435CC genotype was more frequent in controls
(31% versus 16% in CIA patients). Homozygous mutant (3435TT)
patients had a threefold higher chance on developing CIA
(Table 3). In contrast, we observed a trend towards less CIA
patients having the ABCB1 2677 TT genotype (10%) compared with
controls (20%, P= 0.07). On the basis of these data, testing for
ABCB1 3435TT would have a sensitivity of 32% and a specificity of
80%, with a negative predictive value of 90%.
When comparing neutropenia patients with controls, again the
risk of having neutropenia was about threefold higher in patients
with the ABCB1 3435TT genotype; the ABCB1 3435TT genotype was
more frequent in neutropenia patients (34% versus 20% in
controls) and the wild-type ABCB1 3435CC genotype was more
frequent in controls (31% versus 18% in neutropenia patients;
P= 0.05; Table 3). The GSTP1 313GG appears to be more frequent
in neutropenia patients (25% versus 10% in controls), with an odds
ratio of 2.5, this is not statistically significant due to the small
sample size. GSTT1 deficiency was more frequently observed in
neutropenia patients (31% versus 14% in control patients; P= 0.03;
Table 3), with an odds ratio of 2.64 (Table 4). In contrast, 33% of
neutropenia patients lacked the gene of GSTM1, compared to 53%
in the control group. This difference does not appear to be
statistically significant (OR= 0.45).
DISCUSSION
Agranulocytosis is a very serious, life-threatening adverse effect of
clozapine occurring in 0.4–0.8% of the patients. Although the
Table 2a. Patient information
Population (N) Male/female Age at lowest ANC Clozapine dose Plasma level Lifetime duration clozapine
treatment (months)
Agranulocytose 31 20 (65%)/11 (35%) 46.2± 14.8 331± 170 354± 344 57.9± 62.5
Neutropenia 38 21 (55%)/17 (45%) 44.2± 16.9 240± 139 240± 146 40.0± 46
Control 241 165 (68%)/76 (32%) 43.9± 19.1 345± 187 253± 105 67.8± 49
Total 310 206 (66%)/104 (34%) 44.2± 17.0 332± 184 264± 157 63.8± 50.4
Table 2b. Co-medication
Number Valproic acid use Carbomazepine use Olanzapine use
Number Average dose (mg) Number Average dose (mg) Number Average dose (mg)
Agranulocytosis 31 4 (13%) 1438± 597 1 (3%) 600 0 NA
Neutropenia 38 3 (8%) 900± 361 3 (8%) 433± 153 1 (3%) 15
Control 241 24 (10%) 1283± 457 2 (1%) 400± 0 5 (2%) 12± 12
Total 310 31 (10%) 1266± 471 6 (2%) 450± 122 6 (2%) 13± 7
Abbreviation: NA, not applicable.
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exact mechanism remains to be established, formation of
reactive metabolites such as nitrenium ions are considered to
have a role in development of CIA.46,47 In addition, CIA is thought
to be immune mediated.48 Therefore, variability in activity of the
enzymes involved in bioactivation and inactivation as well as
enzymes involved in immune reactions might be important
factors determining interindividual susceptibility for these adverse
drug reactions. In our study we tested whether polymorphisms in
genes encoding such enzymes may serve as genetic predictors for
CIA or neutropenia.
In the present study, a higher frequency of the NQO2 1541A
allele was found for CIA patients, compared with control patients.
Herewith, we confirm the findings of an Israeli study, with 98
clozapine users and 18 CIA patients (Table 5, ref. 24). In contrast
with Ostrousky’s study, where all CIA patients were heterozygous
for NQO2 1541G4A, also patients that were homozygous wild
type or mutant were represented in the patients with CIA. Still, the
allele frequencies in control and CIA patients are comparable, as
are the numbers of 1541A carriers in either group (47 and 51% in
controls and 71 and 100% in CIA patients, this study versus
Ostrousky et al.24). The NQO2 G1541A mutation results in
disruption of the MZF1 binding site.24 MZF1 is specifically
expressed in myeloid cells and essential for granulopoiesis.25
NQO2 mRNA expression was found to be lower in neutrophils of
CIA patients than in control patients.24 Functional studies on the
detoxification of clozapine metabolites by NQO2, however, are
warranted to support the results.
Previously, the importance of NQO1 in neutrophiles was
demonstrated using NQO1− /− mice, which were shown to be
resistant to mitomycin-C-induced neutropenia.49 In humans,
mutation NQO1 C609T is associated with reduced NQO1 activity.
An association study in benzene-exposed adult Chinese workers
showed NQO1 C609T is associated with greater risk of neutrope-
nia, indicative for a protective role of NQO1 in human neu-
trophils.50 However, in the present study no association was found
between NQO1 C609T and CIA, indicating that the enzyme
function per se is not indicative of the development of CIA. The
different substrate selectivities of NQO1 and NQO2 might explain
their different contribution in protection against benzene and
clozapine neutropenia.
A role for P-gp, a cell membrane-bound efflux pump encoded
for by the ABCB1 gene, in clozapine transport across blood cell
membranes has not yet been established. In the current study, the
homozygous presence of ABCB1 3435TT seems to be a risk factor
Table 3. Allele and genotype frequencies for CIA, neutropenia and control patients
Allele frequency Homozygote frequencya P-valuea
Control Neutropenia CIA Control Neutropenia CIA Neutropenia CIA
ABCB1 2677T 0.45 0.46 0.31 0.20 0.24 0.10 0.82 0.07
ABCB1 3435T 0.44 0.58 0.58 0.20 0.34 0.32 0.05 0.05
CYBA 640A 0.51 0.42 0.53 0.26 0.16 0.29 0.14 1.00
HLA-DQB1 6672G 0.96 0.96 0.95 0.93 0.93 0.90 1.00 0.70
Hsp70-2 1267G 0.44 0.47 0.52 0.18 0.21 0.29 0.61 0.29
NQO1 609T 0.19 0.26 0.11 0.03 0.03 0.00 1.00 0.60
NQO2 1541A 0.27 0.20 0.47 0.07 0.03 0.23 0.32 0.004b
MPO -463A 0.23 0.33 0.23 0.07 0.11 0.16 0.26 0.37
TNF -308A 0.14 0.16 0.19 0.02 0.03 0.00 0.52 1.00
GSTA1 -69T 0.41 0.33 0.39 0.16 0.11 0.16 0.31 1.00
GSTP1 313G 0.37 0.44 0.40 0.10 0.25 0.10 0.10 0.73
GSTT1null 0.14 0.31 0.13 0.14 0.31 0.13 0.03 1.00
GSTM1null 0.53 0.33 0.48 0.53 0.33 0.48 0.05 0.71
Abbreviation: CIA, clozapine-induced agranulocytosis. aRegarding homozygous presence of indicated allele. bSignificant difference between neutropenia and
CIA patients (P = 0.01).
Table 4. Odds ratios and 95% confidence intervals for CIA, neutropenia and control patients
Control versus neutropenia Control versus CIA Control versus neutropenia+CIA
ORa 95% CI ORa 95% CI ORa 95% CI
ABCB1 2677T 1.12 0.44–2.85 0.30 0.08–1.08 0.66 0.31–1.43
ABCB1 3435T 2.90 1.08–7.79 3.13 1.01–9.70 2.99 1.36–6.57
CYBA 640A 0.44 0.16–1.26 1.14 0.40–3.27 0.70 0.33–1.51
HLA-DQB1 6672G 1.03 0.19–5.66 0.71 0.16–3.20 0.84 0.23–3.06
Hsp70-2 1267G 1.32 0.48–3.60 1.86 0.67–5.18 1.56 0.73–3.35
NQO1 609T 1.87 0.94–3.72 0.55 0.23–1.32 1.13 0.65–1.97
NQO2 1541A 0.30 0.04–2.33 5.53 1.83–16.68 1.72 0.69–4.31
MPO –463Ab 1.85 0.93–3.69 1.24 0.58–2.62 1.54 0.90–2.64
TNF –308Ab 0.87 0.41–1.85 0.56 0.26–1.22 0.71 0.24–1.77
GSTA1 –69T 0.53 0.16–1.68 0.88 0.29–2.66 0.66 0.29–1.57
GSTP1 313G 2.48 0.95–6.50 1.19 0.30–4.76 1.95 0.85–4.51
GSTT1null 2.64 1.19–5.86 0.89 0.29–2.70 1.73 0.88–3.41
GSTM1null 0.45 0.22–0.95 0.85 0.40–1.79 0.61 0.35–1.06
Abbreviations: CI, confidence interval; CIA, clozapine-induced agranulocytosis; OR, odds ratio. aRegarding homozygous presence of indicated allele versus
homozygous presence of other allele. bRegarding homo- or heterozygous presence of indicated allele. Bold values indicate significant result P40.05.
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for clozapine-induced decrease of neutrophils. The low frequency
of the ABCB1 3435CC genotype in CIA patients suggests a
protective effect of ABCB1 3435CC against lethal neutrophil
diseases. Henning et al.51 showed that inhibitors of P-gp did not
alter intracellular accumulation of clozapine in HL-60 cells.51
However, the level of expression and activity of P-gp does depend
on the type of blood cell.52 Also literature on ABCB1 G2677A/T,
resulting in the amino-acid substitution A893S/T, does not provide
a definite conclusion on the effect of this polymorphism on
expression or function of the transporter in vivo. Depending on
patient groups or cell type, the ABCB1 2677G allele was associated
with increased, decreased or similar transcription and/or expres-
sion levels.53–57 Both the ABCB1 2677GG genotype and the ABCB1
3435CC were associated with reduced serum levels of clozapine,
ABCB1 3435CC showing the most prominent effects.34,35 Clozapine
concentrations in neutrophils could well be increased for patients
homozygous for ABCB1 2677GG or 3435CC, despite lower serum
levels. A case report describing a normal clozapine serum level,
but abnormally high clozapine levels in neutrophils in a CIA
patient does indicate a role for clozapine transporters in CIA.37 In
literature no direct relationship has been observed between
clozapine serum levels and leukocyte counts, most likely because
cellular uptake, bioactivation and inactivation are important
factors.
ABCB1 G2677T and C3435T are reported to be genetically
linked,58 as was the case in our study (data not shown). However,
although we find comparable allele frequencies in control
patients, the 3435T allele was more frequent in CIA, whereas the
2677T frequency was lower. In a previous study, mutation ABCB1
C3435T, but not G2677T, was found to be related to neutropenia
induced by the antitumor agent amrubicin in lung cancer
patients.59 These results and our results suggest that the mutation
C3435T might have a more prominent effect on ABCB1 activity
than G2677T.
For CYBA 640 and MPO-463 our results do not notably differ
from those obtained in another study (Table 5).20 However, for
Hsp70-2 1267 we could not reproduce the results obtained by
Corzo et al.16 (Table 5): although we did find an OR that
approximates the reported one, our findings do not reach
statistical significance. The small overall sample size of the former
study and the limited number of cases in both studies are likely
the cause of this discrepancy.
GSTM1, GSTA1 and GSTP1 were shown to be involved in
glutathione conjugation of the nitrenium ion of clozapine, GSTP1
having the highest activity.27 In the present study, GSTP1
polymorphism was not associated with either CIA or neutro-
penia, which can be explained by the fact that the mutation only
has a minor effect on inactivation of the reactive nitrenium ion of
clozapine.60 Although GSTT1 appeared to be inactive in inactiva-
tion of this reactive metabolite,27 an overrepresentation
of GSTT1null genotype in patients with clozapine-induced
neutropenia was found in this study. Deficiency of GSTM1 was
less frequent in patient with neutropenia, therefore seems a
protective factor. Deficiency of GSTM1 was found previously to
cause resistance against acetaminophen-induced hepatotoxicity
in mice, by disrupting a cellular pathway involved in cytotoxicity.61
Whether a similar mechanism might be applicable in neutrophiles
remains to be established.
HLA-DQB1 6672C has been associated with CIA previously,62
and even the pharmacogenetic test PGxPredict:CLOZAPINE
(PGxHealth, New Haven, USA, discontinued in March 2011) was
based on this polymorphism. Furthermore, in a recent GWAS
study on 98 CIA cases, an amino-acid substitution in HLA-DQB1
that is in linkage disequilibrium with the 6672C SNP was found to
be associated with CIA.63 The results of the present study did
not confirm these associations, (Table 5) although the overall
frequencies of both cases and controls combined were compar-
able (9%15 versus 8% in our study), the previously reported
frequency of the marker in cases versus control (22 versus 2%,
Table 5))15 differs notably from our findings (10 versus 7%).
It is conceivable that, for example, an aberrant transport of
clozapine, resulting in increased intracellular levels, poses a much
greater risk for CIA if combined with an aberrant reaction of
neutrophils to stress. However, we could not find such combina-
tions in our study since our sample size does not allow for finding
combined genetic predictors. Of note, with a prevalence of
0.4–0.8% for CIA and 3% for neutropenia, it is challenging to
include more cases. Further limitations of this study are the
variations in dose, co-medication and treatment duration. Which
are related to the retrospective structure of the study. Dose
variations were previously shown not to influence the occurrence
of CIA.36 Treatment duration was used as a selection criterion for
control patients. Co-medication was limited (Table 2b) and did not
vary between groups.
In conclusion, this study describes 31 patients who developed
clozapine-induced agranulocytosis and 38 patients who devel-
oped neutropenia in a group of 310 clozapine users. The most
significant association with CIA was found with mutation NQO2
G1541A, making it one of the candidate markers for the prediction
of CIA, with in this study a specificity of 97% and a sensitivity of
23%. Furthermore, an association was found between CIA and a
P-gp transporter polymorphism (ABCB1 3435T) for the first time.
So far the predictive value of individual genetic polymorphisms is
not strong enough to predict CIA with high accuracy. Therefore
most likely combinations of risk factors, such as increased
cellular uptake, high bioactivation, low bioinactivation, and
immunological factors are required to result in CIA. Much larger
association studies, allowing the study of combinations of
genetic markers and risk factors, will be required to identify the
high-risk combinations for clozapine-induced agranulocytosis and
neutropenia.
Table 5. Results from other studies control versus CIA
Allele frequency Homozygote frequencya
Control CIA Control CIA P-valuea ORb 95% CI Cases/controls
CYBA 640A19 0.40 0.41 0.19 0.31 0.09 2.26 0.96–5.35 78/75
HLA-DQB1 6672G58 0.99 0.89 0.98 0.78 o0.001 0.06 0.01–0.26 79/125
Hsp70-2 1267G15 0.59 0.78 0.35 0.56 0.01 2.40 0.9–6.14 32/43
NQO2 1541A23 0.28 0.50 0.05 0.00 o0.001 ND ND 18/80
MPO -463Ab,19 0.20 0.22 0.03 0.10 0.11 1.12 0.59–2.14 81/78
MPO -463Ab,20 0.19 0.23 0.01 0.06 0.21 0.90 0.38–2.14 31/77
Abbreviations: CI, confidence interval; CIA, clozapine-induced agranulocytosis; ND, not determined; OR, odds ratio. aRegarding homozygous presence of
indicated allele. bRegarding homo- or heterozygous presence of indicated allele.
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